Cypherpunk Technologies (CYPH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 18, 2026, with voting available online, by phone, mail, or during the meeting.
Proxy materials are distributed electronically to reduce costs and environmental impact, with printed copies available upon request.
The meeting will address director elections, executive compensation, auditor ratification, and other business.
Forward-looking statements highlight risks related to digital assets, regulatory changes, and market volatility.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class III directors for terms ending in 2029.
An advisory say-on-pay vote on executive compensation is included.
Ratification of EisnerAmper LLP as independent auditors for 2026 is proposed.
Shareholder proposals and nominations for future meetings must follow specific deadlines and procedures.
Board of directors and corporate governance
The board is divided into three classes with staggered three-year terms; after the meeting, there will be eight active directors.
Board committees include audit, compensation, and nominating/governance, each with defined charters and independent members.
The roles of CEO and Chairman are separated, with a Lead Independent Director providing additional oversight.
Directors are evaluated for independence and diversity of experience; regular executive sessions are held.
Latest events from Cypherpunk Technologies
- Q2 2026 profit surged on ZEC gains; lead cancer drug advanced to Phase 3 with FDA support.CYPH
Q2 2026 - Director elections, compensation, and auditor ratification passed with strong shareholder support.CYPH
AGM 2026 - $77.2M Q1 loss driven by ZEC volatility; Zcash holdings and clinical progress highlighted.CYPH
Q1 2026 - Virtual annual meeting set for June 18, 2026, with key votes on directors, pay, and auditor.CYPH
Proxy filing - Returned to profitability in 2025 with strong ZEC gains, new capital, and clinical progress.CYPH
Q4 2025 - Shareholders approved key proposals including share increase, reverse split, and new equity plan.CYPH
AGM 2025 - Phase 2 trials for DKN-01 in gastric and colorectal cancer near key data readouts and expansion.CYPH
Piper Sandler 36th Annual Healthcare Conference - Sirexatamab improved response rates in CRC, especially in DKK1-high and VEGF-naive patients.CYPH
Study Result - Sirexatamab shows strong efficacy in GI cancer trials; FL-501 advances toward clinical studies.CYPH
43rd Annual J.P. Morgan Healthcare Conference 2025